307 related articles for article (PubMed ID: 26780555)
1. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Kotsopoulos J; Huzarski T; Gronwald J; Moller P; Lynch HT; Neuhausen SL; Senter L; Demsky R; Foulkes WD; Eng C; Karlan B; Tung N; Singer CF; Sun P; Lubinski J; Narod SA
Breast Cancer Res Treat; 2016 Jan; 155(2):365-73. PubMed ID: 26780555
[TBL] [Abstract][Full Text] [Related]
2. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Kotsopoulos J; Gronwald J; Karlan BY; Huzarski T; Tung N; Moller P; Armel S; Lynch HT; Senter L; Eisen A; Singer CF; Foulkes WD; Jacobson MR; Sun P; Lubinski J; Narod SA;
JAMA Oncol; 2018 Aug; 4(8):1059-1065. PubMed ID: 29710224
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
5. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
Eisen A; Lubinski J; Gronwald J; Moller P; Lynch HT; Klijn J; Kim-Sing C; Neuhausen SL; Gilbert L; Ghadirian P; Manoukian S; Rennert G; Friedman E; Isaacs C; Rosen E; Rosen B; Daly M; Sun P; Narod SA;
J Natl Cancer Inst; 2008 Oct; 100(19):1361-7. PubMed ID: 18812548
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
[TBL] [Abstract][Full Text] [Related]
7. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Wagner T; Lynch HT; Garber JE; Daly MB; Isaacs C; Olopade OI; Neuhausen SL; van 't Veer L; Eeles R; Evans DG; Tomlinson G; Matloff E; Narod SA; Eisen A; Domchek S; Armstrong K; Weber BL;
J Clin Oncol; 2005 Nov; 23(31):7804-10. PubMed ID: 16219936
[TBL] [Abstract][Full Text] [Related]
8. Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea.
Kim HY; Park J; Moon SJ; Jeong S; Hong JH; Lee JK; Cho GJ; Cho HW
Cancer Res Treat; 2024 Jan; 56(1):143-148. PubMed ID: 37591780
[TBL] [Abstract][Full Text] [Related]
9. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
[TBL] [Abstract][Full Text] [Related]
10. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
11. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
Kotsopoulos J; Lubinski J; Moller P; Lynch HT; Singer CF; Eng C; Neuhausen SL; Karlan B; Kim-Sing C; Huzarski T; Gronwald J; McCuaig J; Senter L; Tung N; Ghadirian P; Eisen A; Gilchrist D; Blum JL; Zakalik D; Pal T; Sun P; Narod SA;
Breast Cancer Res Treat; 2014 Feb; 143(3):579-86. PubMed ID: 24458845
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
13. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
Huber D; Seitz S; Kast K; Emons G; Ortmann O
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2035-2045. PubMed ID: 33885953
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
17. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Kim-Sing C; Neuhausen S; Demsky R; Foulkes WD; Ghadirian P; Tung N; Ainsworth P; Senter L; Karlan B; Eisen A; Eng C; Weitzel J; Gilchrist DM; Blum JL; Zakalik D; Singer C; Fallen T; Ginsburg O; Huzarski T; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1089-96. PubMed ID: 22564871
[TBL] [Abstract][Full Text] [Related]
18. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk.
Shantakumar S; Terry MB; Paykin A; Teitelbaum SL; Britton JA; Moorman PG; Kritchevsky SB; Neugut AI; Gammon MD
Am J Epidemiol; 2007 May; 165(10):1187-98. PubMed ID: 17337757
[TBL] [Abstract][Full Text] [Related]
19. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
20. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
